Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time? [PDF]
Interact Cardiovasc Thorac Surg, 2022 Monteagudo-Vela M +4 more
europepmc +1 more source
Age-associated developmental changes in the activated partial thromboplastin time (APTT) and causes of prolonged APTT values in healthy Chinese children [PDF]
, 2009 Jianxin Li +7 more
openalex +1 more source
Activated Protein C Resistance Testing: An Update From Australasia/Asia‐Pacific
International Journal of Laboratory Hematology, Volume 47, Issue 4, Page 720-729, August 2025.ABSTRACT Introduction Activated protein C resistance (APCR) represents a risk factor for thrombosis and is usually due to factor V Leiden (FVL). Clinicians may order either test (i.e., APCR or FVL) to help assess ‘thrombophilia’ in patients who present with thrombosis. APCR testing is usually achieved using clot‐based assays, whereas FVL is assessed by
Emmanuel J. Favaloro +8 more
wiley +1 more source
Activated Partial Thromboplastin Time and Anti-IIa Monitoring in Argatroban Anticoagulation in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation. [PDF]
Clin Appl Thromb HemostBurša F +10 more
europepmc +1 more source
A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy. [PDF]
Hamostaseologie, 2023 Liu Y, Yuan Z, Han X, Song K, Xing J.
europepmc +1 more source
Effect of Body Mass Index on Bleeding Frequency and Activated Partial Thromboplastin Time in Weight-Based Dosing of Unfractionated Heparin: A Retrospective Cohort Study [PDF]
, 2009 Seth R. Bauer +6 more
openalex +1 more source
Houston, we have a problem: Coagulation concerns during long‐term spaceflight
Experimental Physiology, EarlyView.
Lewis Fall, Damian M. Bailey
wiley +1 more source
Advanced Science, Volume 12, Issue 26, July 10, 2025.Occlusion of tumor blood vessels represents a promising yet challenging approach in cancer treatment. Herein, supramolecularly engineered platelets conjugated with morphology‐transformable nanoparticles is developed for precise tumor embolization. The engineered platelets actively accumulate at tumor sites following induced blood vessel injury.
Junyan Li +9 more
wiley +1 more source
The evaluation of prothrombin time and activated partial thromboplastin time among diabetic and healthy controls in Africa: systematic review and meta-analysis. [PDF]
Front Med (Lausanne)Getu F +4 more
europepmc +1 more source